Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax CCHFV vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intraperitoneal, Parenteral
01
Overview
VesiculoVax CCHFV vaccine is a preclinical-stage, replication-competent viral vector vaccine developed by Auro Vaccines in collaboration with the National Institutes of Health (NIH) and the University of Texas Medical Branch (UTMB). The vaccine utilizes the VesiculoVax platform, which employs an attenuated, negative-strand, non-segmented RNA vesicular stomatitis virus (VSV) vector engineered to express the surface glycoproteins of the Crimean-Congo hemorrhagic fever virus (CCHFV). This approach is designed to present CCHFV antigens in their authentic form, stimulating the production of neutralizing antibodies and activating innate immune signals to provide durable protection against Crimean-Congo hemorrhagic fever (CCHF), a severe tick-borne viral disease.
- Other names
- VesiculoVax CCHFVVSV-CCHFV vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on VesiculoVax CCHFV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax CCHFV vaccine.